Skip to main navigation

Contact Us
Join Us
LinkedIn

Our Company
Our Areas of Focus
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor
  - NAION | Privosegtor
- Ophthalmology
  - Dry Eye Disease | Licaminlimab
Our Innovation
Investors and Media
- Column
- Column

Our Company
Our Areas of Focus
- Neuro-Ophthalmology
  - Optic Neuritis I Privosegtor Diabetic Macular Edema I OCS-01
  - NAION | Privosegtor Dry Eye Disease I Licaminlimab
- Ophthalmology
  - Dry Eye Disease | Licaminlimab Post-Ocular Surgery
Our Innovation
Investors and Media
- Column
- Column

Event Details

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Overview
Stock
Releases
In the News
Events
Governance
SEC Filings
Disclosures
FAQs
Resources
Extra menu
Extra menu
Extra menu

Q2-2026 Earnings Release

Aug 6, 2026

Visionary Innovation

Our Company
About Us
Governance
Our Culture
Contact Us
Join Us
LinkedIn

Our Areas of Focus
Neuro-Ophthalmology
Optic Neuritis I Privosegtor
NAION I Privosegtor
Ophthalmology
Dry Eye Disease I Licaminlimab

Our Innovation
Pipeline
Clinical Trials
Expanded Access Policy
Science
Publications

Investors and Media
Overview
Stock Information
News Releases
In the News
Events & Presentations
Corporate Governance
SEC Filings
Public Disclosures
Investor FAQs
Investor Resources

© 2026 Oculis All Rights Reserved

Terms of Use
Privacy Notices
Cookie Policy
Expanded Access Policy